Ignite Creation Date:
2024-05-06 @ 2:08 PM
Last Modification Date:
2024-10-26 @ 1:25 PM
Study NCT ID:
NCT04227028
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-07
First Post:
2020-01-10
Brief Title:
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced Metastatic or Recurrent NSCLC
Sponsor:
Organization:
City of Hope Medical Center